Rare diseases
Investigational molecules
Locations
900 Winter Street, 02451-1449, United States
Alkermes Inc. is active in clinical research focused on narcolepsy and idiopathic hypersomnia, with studies addressing both narcolepsy type 1 and narcolepsy type 2.
The sponsor’s trial portfolio reflects a strong therapeutic interest in disorders that disrupt alertness, sleep continuity, and daytime functioning.
Alkermes Inc. runs clinical trials in conditions such as Narcolepsy, Hypersomnia, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
AustriaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaLong-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2
BelgiumStudy of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia
BelgiumStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 2
BelgiumStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 1
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
